PT  - JOURNAL ARTICLE
AU  - Abedi, Majid R.
AU  - Dixon, Samuel
AU  - Guyon, Timothy
AU  - Hsu, Serene
AU  - Jacobs, Aviva R.
AU  - Nair, Lakshmi
AU  - Terbrueggen, Robert
TI  - Predicting COVID-19 Vaccine Efficacy from Neutralizing Antibody Levels
AID  - 10.1101/2021.10.13.21264921
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.10.13.21264921
4099  - http://medrxiv.org/content/early/2021/10/18/2021.10.13.21264921.short
4100  - http://medrxiv.org/content/early/2021/10/18/2021.10.13.21264921.full
AB  - Recent studies using data accrued from global SARS-CoV-2 vaccination efforts have demonstrated that breakthrough infections are correlated with levels of neutralizing antibodies. The decrease in neutralizing antibody titers of vaccinated individuals over time, combined with the emergence of more infectious variants of concern has resulted in waning vaccine efficacy against infection and a rise in breakthrough infections. Here we use a combination of neutralizing antibody measurements determined by a high throughput surrogate viral neutralization test (sVNT) together with published data from vaccine clinical trials and comparative plaque reduction neutralization test (PRNT) between SARS-CoV-2 variants to develop a model for vaccine efficacy (VE) against symptomatic infection. Vaccine efficacy estimates using this model show good concordance with real world data from the US and Israel. Our work demonstrates that appropriately calibrated neutralizing antibody measurements determined by high throughput sVNT can be used to provide a semi-quantitative estimate of protection against infection. Given the highly variable antibody levels among the vaccinated population, this model may be of use in identification of individuals with an elevated risk of breakthrough infections.Competing Interest StatementAll authors are current or former employees of DxTerity Diagnostics and have stock or stock options in the the company.Funding StatementThe study was funded by DxTerity DiagnosticsAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The WCG IRB gave ethical ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study will be made available at reasonable request to authors once published in a peer reviewed journal